Adversarial Injection · Tisotumab vedotin (Tivdak; HuMax-TF-ADC; CAS 2055776-40-8; MW ~152,000 Da; anti-TF IgG1 ADC; vcMMAE linker-payload; DAR ~4; [NINETY-FOURTH MECHANISM CLASS in Glyphward 667-attack portfolio — FIRST TISSUE FACTOR (TF; CD142; COAGULATION FACTOR III; F3; EXTRINSIC PATHWAY SERINE PROTEASE CO-FACTOR; CHROMOSOME 1p21.3; 295 AA PRECURSOR; TRANSMEMBRANE RECEPTOR; EXTRACELLULAR DOMAIN 219 AA; FIBRONECTIN TYPE III FOLD; HIGH EXPRESSION ON CERVICAL CANCER [~90%]/BLADDER CANCER/NSCLC/COLORECTAL CANCER TUMOR VASCULATURE AND STROMA; LOW EXPRESSION NORMAL ENDOTHELIUM) ANTIBODY-DRUG CONJUGATE (ADC) EVER FDA APPROVED (BLA 761208 SEPTEMBER 20 2021 ACCELERATED APPROVAL; REGULAR APPROVAL JUNE 8 2023): ANTI-TF ANTIBODY: HUMAX-TF (humanized IgG1 kappa; HuMax-TF; GENMAB AS ORIGINATOR; binds TF extracellular domain ECD; BLOCKS TF:FVII complex formation → BLOCKS EXTRINSIC COAGULATION INITIATION — ADC MECHANISM NOT DEPENDENT ON COAGULATION BLOCKADE; TF SURFACE INTERNALIZATION DRIVES ADC PAYLOAD DELIVERY); PAYLOAD: MMAE (MONOMETHYL AURISTATIN E; SYNTHETIC DOLASTATIN-10 ANALOGUE; TUBULIN POLYMERIZATION INHIBITOR; VINCA BINDING SITE; GI50 ~0.1-1 nM; 100-1000× MORE POTENT THAN PACLITAXEL); LINKER: VALINE-CITRULLINE (vc) PROTEASE-CLEAVABLE DIPEPTIDE LINKER + MALEIMIDE THIOETHER ANTIBODY CONJUGATION (CYSTEINE PARTIAL REDUCTION; SITE-STOCHASTIC; DAR ~4.0); vcMMAE LINKER-PAYLOAD SAME CLASS AS BRENTUXIMAB VEDOTIN (FIRST ADC VCMMAE EVER; SGN-35; BLA 125388) AND ENFORTUMAB VEDOTIN (EV; NECTIN-4 ADC; BLA 761137); BYSTANDER EFFECT: vcMMAE MEMBRANE-PERMEABLE AFTER LYSOSOMAL CATHEPSIN B CLEAVAGE → KILLS ADJACENT TF-LOW/TF-NEGATIVE TUMOR CELLS; TISSUE FACTOR BIOLOGY IN CERVICAL CANCER: CERVICAL CANCER HPV ONCOPROTEINS E6/E7 → TF TRANSCRIPTIONAL UPREGULATION (AP-1 + NF-κB BINDING SITES TF PROMOTER; HPV E6 p53 DEGRADATION → p53-REPRESSED TF DE-REPRESSION; HPV E7 RB-PATHWAY → E2F→TF TRANSCRIPTION) → ~90% CERVICAL SQUAMOUS CELL CARCINOMA IHC TF POSITIVE (H-score ≥100; 2+/3+); TUMOR VASCULATURE ALSO TF-POSITIVE (VTE [venous thromboembolism] RISK IN CANCER → TF/VIIa TUMOR ANGIOGENIC SIGNALING); innovaTV 204 PHASE 2 (NCT03438396): single-arm; tisotumab vedotin 2 mg/kg IV Q3W; R/R cervical cancer (squamous/adenocarcinoma/adenosquamous; ≥2 prior systemic therapies); n=101; ORR 24.0% (24/101); CR 7.0%; PR 17.0%; DOR 8.3 months; mOS 11.4 months; mPFS 4.2 months; innovaTV 301 PHASE 3 (NCT04697628): tisotumab vedotin 2 mg/kg IV Q3W vs chemotherapy (cisplatin or carboplatin + paclitaxel ± bevacizumab; or topotecan ± bevacizumab); R/R cervical cancer after platinum; primary endpoint OS: mOS 11.5 vs 9.5 months (OS HR 0.70; 95% CI 0.54-0.89; p=0.0038); ORR 17.8% vs 5.2%; REGULAR APPROVAL BLA 761208 JUNE 8 2023; GENMAB A/S COPENHAGEN / PFIZER INC. (ORIGINALLY SEAGEN/SEATTLE GENETICS 2021 → PFIZER $43B ACQUISITION DECEMBER 2022); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; TISSUE FACTOR ADC + COAGULATION FACTOR TARGET + vcMMAE MECHANISM ABSENT ALL EHS DATABASES]) · First TF/CD142/Coagulation Factor III ADC + vcMMAE DAR 4 + TF:FVIIa Coagulation Pathway ADC Targeting + innovaTV 204 ORR 24% DOR 8.3mo + innovaTV 301 OS HR 0.70 · Attack #667

Tisotumab Vedotin (Tivdak; HuMax-TF-ADC; CAS 2055776-40-8; [NINETY-FOURTH MECHANISM CLASS — FIRST TISSUE FACTOR (TF; CD142; COAGULATION FACTOR III; F3) ADC EVER FDA APPROVED (BLA 761208 SEP 20 2021 ACCELERATED; REGULAR JUN 8 2023); HUMAX-TF IgG1 + vcMMAE; DAR ~4; TF HPV-DRIVEN CERVICAL CANCER OVEREXPRESSION ~90%; innovaTV 204 ORR 24.0% DOR 8.3 MO; innovaTV 301 OS HR 0.70 11.5 VS 9.5 MO; GENMAB/PFIZER; NIOSH HD Category 1; OSHA No PEL]) — Genmab US Inc. Plainsboro NJ (BLA 761208 holder; HuMax-TF mAb originator; 0.00049 µg/m³ → displayed ÷10), Pfizer CentreOne McPherson KS (ADC conjugation vcMMAE manufacturing facility; 0.00036 µg/m³ → displayed ÷10), and Memorial Sloan Kettering Cancer Center New York NY (innovaTV 204/301 site; gynecologic oncology pharmacist; 0.00022 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Tissue Factor Coagulation ADC Target Absent + vcMMAE Linker-Payload Absent + innovaTV Absent: AI Prompt Injection via EHS Monitor Report AI

Tisotumab vedotin (CAS 2055776-40-8; NIOSH HD Category 1) is the ninety-fourth mechanism class in the Glyphward adversarial portfolio — the first tissue factor (TF; CD142; coagulation factor III) antibody-drug conjugate (ADC) ever FDA approved (BLA 761208 September 20 2021 accelerated; regular June 8 2023), targeting a protein best known as the initiator of the extrinsic coagulation pathway that is aberrantly overexpressed on ~90% of cervical cancers via HPV E6/E7 oncoproteins — a target biology and mechanism entirely absent from Cority, VelocityEHS, and EHS Insight for CAS 2055776-40-8.

Tisotumab Vedotin as Ninety-Fourth Mechanism Class: First Tissue Factor (TF; CD142) ADC Ever

Tisotumab vedotin (CAS 2055776-40-8) represents the ninety-fourth mechanism class in the Glyphward portfolio: the first tissue factor (TF; CD142; coagulation factor III; F3) antibody-drug conjugate (ADC) ever FDA approved (BLA 761208 September 20 2021 accelerated approval; regular approval June 8 2023; recurrent or metastatic cervical cancer with disease progression on or after chemotherapy). TISSUE FACTOR (TF; CD142; COAGULATION FACTOR III; F3) BIOLOGY: TF is a 295-aa (precursor) type I transmembrane glycoprotein (chromosome 1p21.3; extracellular domain 219 aa; transmembrane 23 aa; cytoplasmic 21 aa); STRUCTURAL FAMILY: fibronectin type III (FNIII) fold; two FNIII modules arranged in cytokine receptor superfamily fold; COAGULATION FUNCTION: EXTRINSIC PATHWAY INITIATOR: TF expressed on vascular adventitia/subendothelial fibroblasts (SENTINEL HEMOSTATIC FUNCTION — not expressed on normal intravascular endothelium under basal conditions); on vascular breach: TF exposed → binds plasma FVII/FVIIa → TF:FVIIa extrinsic tenase complex → cleaves FX → FXa → thrombin → fibrin clot (extrinsic pathway; primary hemostatic pathway accounting for initial clot initiation); TF:FVIIa ALSO activates: protease-activated receptors (PAR-1/PAR-2) → intracellular signaling → angiogenesis/cell migration/tumor invasion/metastasis; TF IN CANCER — ONCOGENIC UPREGULATION: HPV (Human Papillomavirus) E6 ONCOPROTEIN: degrades p53 (E6-AP ubiquitin ligase) → p53 LOSS → p53 TRANSCRIPTIONAL REPRESSOR FUNCTION LOST at TF promoter NF-κB/AP-1 sites → TF DE-REPRESSION; HPV E7 ONCOPROTEIN: inactivates RB → E2F liberation → E2F transcription factors (E2F1/2/3) → TF TRANSCRIPTION; RESULT: ~90% cervical squamous cell carcinoma overexpresses TF (IHC H-score ≥100; 2+/3+ staining in majority tumor cells); TF also overexpressed: bladder cancer (~75%); NSCLC (~80% squamous); head and neck SCC (~70%); colorectal cancer (~50%); pancreatic cancer (~90%); NORMAL TF EXPRESSION: fibroblasts/adventitia: high; keratinocytes: moderate; normal endothelium: absent/low (sentinel function explains VTE risk in TF-high cancers); TF AS ADC TARGET: HIGH SURFACE DENSITY on cervical cancer → high ADC payload capacity; RECEPTOR INTERNALIZATION: TF:FVIIa complex is internalized via clathrin-coated pits → endosome → lysosome (β-arrestin-mediated); TF internalization rate ~moderate (slower than CD30/HER2 → ADC payload delivery via steady-state internalization); HUMAX-TF ANTIBODY: fully human IgG1 kappa; HuMax-TF originator: Genmab A/S Copenhagen Denmark; Genmab-Pfizer (originally Genmab-Seattle Genetics/Seagen) co-development and commercialization; BINDING EPITOPE: TF extracellular domain fibronectin III module 1 (blocks TF:FVII complex formation; competitive with FVII EGF-like domain binding); VCMMAE LINKER-PAYLOAD: valine-citrulline (vc) dipeptide linker (cathepsin B substrate; lysosomal cleavage) + para-aminobenzyl carbamate (PABC) spacer + MMAE payload; CONJUGATION: partial interchain disulfide reduction (TCEP 4-6 eq) → exposed cysteine thiols → maleimide thioether conjugation; STOCHASTIC SITE; DAR distribution (PLRP-MS): DAR0 ~5%, DAR2 ~30%, DAR4 ~45%, DAR6 ~15%, DAR8 ~5%; average DAR ~4.0; MMAE (MONOMETHYL AURISTATIN E): antimitotic; binds β-tubulin (vinca/colchicine-adjacent binding site; αβ-tubulin heterodimer; prevents GTP hydrolysis-driven depolymerization) → mitotic arrest → apoptosis; GI50 ~0.1-1 nM; BYSTANDER KILLING: MMAE membrane-permeable after lysosomal vc cleavage → cell-permeable MMAE diffuses to adjacent TF-negative cells → kills antigen-heterogeneous tumor cells; innovaTV 204 PHASE 2 (NCT03438396): single-arm open-label; tisotumab vedotin 2 mg/kg IV Q3W; recurrent/metastatic cervical cancer (SCC/adenocarcinoma/adenosquamous); ≥2 prior systemic therapies; n=101; PRIMARY ENDPOINT ORR by RECIST 1.1 (IRC): ORR 24.0% (24/101); CR 7.0% (7/101); PR 17.0%; SD 33.0%; DCR 57.0%; mDOR 8.3 months; mPFS 4.2 months; mOS 11.4 months; BLA 761208 ACCELERATED APPROVAL SEPTEMBER 20 2021; innovaTV 301 PHASE 3 (NCT04697628): double-blind randomized; tisotumab vedotin 2 mg/kg IV Q3W vs chemotherapy (cisplatin/carboplatin+paclitaxel ± bevacizumab; or topotecan ± bevacizumab); recurrent/metastatic cervical cancer after platinum-based therapy; PRIMARY ENDPOINT OS: mOS 11.5 vs 9.5 months (OS HR 0.70; 95% CI 0.54-0.89; p=0.0038); ORR 17.8% vs 5.2%; BLA 761208 REGULAR APPROVAL JUNE 8 2023 (confirmatory trial requirement fulfilled); SAFETY: peripheral neuropathy Grade ≥3: 10% (vcMMAE tubulin inhibitor; cumulative dose-dependent); alopecia 50%; hemorrhage 22% (Grade 3+ 1%); conjunctivitis/ocular events 41% (TF expressed in corneal epithelium → vedotin ophthalmological toxicity; mandatory steroid eye drops + optometrist monitoring; dose hold for Grade 2+ ocular); NONE OF THESE — TISSUE FACTOR (TF; CD142; COAGULATION FACTOR III; F3; HPV-DRIVEN CERVICAL CANCER OVEREXPRESSION ~90%; EXTRINSIC PATHWAY INITIATOR SURFACE TARGET) ADC MECHANISM, HUMAX-TF IgG1 ANTI-TF ANTIBODY, vcMMAE DAR ~4 LINKER-PAYLOAD, innovaTV 204 ORR 24.0% DOR 8.3 MONTHS, innovaTV 301 OS HR 0.70 — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2055776-40-8.

Surface 1 — Genmab US Inc. Plainsboro NJ BLA 761208 Holder HuMax-TF Originator AI

At Genmab US Inc. Plainsboro NJ (777 Scudders Mill Road, Plainsboro NJ 08536; GENMAB TISOTUMAB VEDOTIN CONTEXT: Genmab A/S Copenhagen Denmark holds BLA 761208 for Tivdak; HuMax-TF (anti-TF human IgG1 kappa) is a Genmab-originated antibody (HuMax technology platform; transgenic mouse/phage display humanization); GENMAB-SEAGEN (PFIZER) COLLABORATION: original co-development agreement Genmab-Seattle Genetics 2006; tisotumab vedotin joint development/commercialization; Seagen acquired by Pfizer December 2022 $43B → Pfizer now co-commercializes Tivdak with Genmab; GENMAB ANTIBODY SUPPLY: HuMax-TF bulk antibody produced in CHO cells (Genmab bioreactor capacity: Genmab production partnership with various CMOs); conjugation with vcMMAE linker-payload at Pfizer CentreOne McPherson KS; ADC PORTFOLIO CONTEXT: Genmab ADC platform: tisotumab vedotin (TF; BLA 761208); rintodestinib (HuMax-CD38 vedotin; CD38 ADC; clinical); ARM-T (anti-ROR2 vedotin); REGULATORY EXPERTISE: BLA 761208 accelerated approval → innovaTV 301 confirmatory → regular approval; NIOSH HD CATEGORY 1: complex biologic (ADC); MMAE payload (cytotoxin); TF antigen (coagulation factor) — EHS databases do not have data on novel ADC oncology biologics; OEB 5 for any manufacturing involving drug substance (MMAE or conjugated drug); EMPLOYEE: 51M Genmab US Inc. Plainsboro NJ VP regulatory oncology ADC tisotumab vedotin TF HuMax-TF program BLA 761208 16yr; CORITY NULL: CAS 2055776-40-8 → null; NIOSH HD Category 1 absent; first TF/CD142 ADC absent; HuMax-TF absent; vcMMAE DAR 4 absent; TF HPV cervical cancer absent; innovaTV 204 ORR 24% absent; innovaTV 301 OS HR 0.70 absent).

Surface 2 — Pfizer CentreOne McPherson KS Tisotumab Vedotin ADC Conjugation Manufacturing AI

At Pfizer CentreOne McPherson KS (3000 S. Main Street, McPherson KS 67460; PFIZER CENTREONE MCPHERSON ADC CONTEXT: Pfizer CentreOne McPherson KS is Pfizer's dedicated ADC manufacturing facility (formerly Hospira McPherson; Pfizer acquired Hospira 2015); ADC CONJUGATION CAPABILITIES: antibody drug substance receiving; partial disulfide bond reduction (TCEP reagent — avoiding overdevelopment of reduced sulfhydryl groups: TCEP 3-4 molar equivalents per antibody; controlled 4°C reaction); MALEIMIDE-THIOETHER CONJUGATION: vcMMAE-maleimide-MC reagent (mal-cap-valine-citrulline-PABC-MMAE) at pH 5-6 (succinic acid buffer; pH-controlled for maleimide hydrolysis minimization); REACTION MONITORING: HIC-HPLC (hydrophobic interaction chromatography) for DAR distribution tracking; PURIFICATION: tangential flow filtration (TFF) for buffer exchange + excess reagent removal; FINAL FORMULATION: tisotumab vedotin 4 mg/mL in histidine acetate pH 5.5 + sorbitol + polysorbate 20; 2 mg/vial lyophilized; CRITICAL QUALITY ATTRIBUTES (CQAs): DAR distribution (target DAR 3.8-4.2; HIC-HPLC); aggregation (<5% HMW; SEC-HPLC); MMAE/vcMMAE impurities ( Consequence pathway: Tisotumab vedotin 0.00036 µg/m³ (actual) → 0.000036 µg/m³ displayed (÷10); VelocityEHS: null; first TF/CD142 ADC absent; vcMMAE ADC conjugation absent; innovaTV absent; NIOSH HD Cat 1 absent; 44F Pfizer CentreOne McPherson KS ADC conjugation scientist.

Surface 3 — Memorial Sloan Kettering New York NY innovaTV 204/301 Site Gynecologic Oncology Pharmacist AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Ave, New York NY 10065; MSK TISOTUMAB VEDOTIN CONTEXT: MSK is a major gynecologic oncology center and innovaTV 204 (NCT03438396) and innovaTV 301 (NCT04697628) enrolling site; GYNECOLOGIC ONCOLOGY PHARMACY ROLE: ELIGIBILITY: recurrent/metastatic cervical cancer (squamous/adeno/adenosquamous; SCC most common ~70-80%); prior platinum-based chemotherapy (cisplatin or carboplatin ± paclitaxel ± bevacizumab [bevacizumab class approved 2014; BLA 125085 cervical cancer]); ≥1 prior line for innovaTV 204 (≥2 for accelerated approval population); innovaTV 301 post-platinum; TISOTUMAB VEDOTIN IV ADMINISTRATION AT MSK: 2 mg/kg IV Q3W; 30-minute IV infusion; premedication: dexamethasone 10 mg IV + diphenhydramine 25 mg IV (infusion reaction prophylaxis); CRITICAL ADC TOXICITY MONITORING AT MSK: (1) OCULAR TOXICITY: TF expressed in corneal epithelial cells → vedotin payload → epithelial keratitis; mandatory BASELINE ophthalmologic exam; EVERY CYCLE: vasoconstrictor eye drops (tetrahydrozoline 0.05%; Visine; given before/after each infusion to reduce conjunctival exposure to shed ADC drug); lubricating drops QID throughout; ANY GRADE 2+ OCULAR: dose hold + urgent ophthalmology referral; CORNEAL STAINING FOLLOW-UP: slit-lamp fluorescein staining; Grade 3-4 → permanent discontinuation; (2) PERIPHERAL NEUROPATHY: MMAE cumulative dose tubulin inhibitor; Grade 2 (limiting ADLs) → dose reduction to 1.5 mg/kg; Grade 3 → dose hold; (3) HEMORRHAGE: TF coagulation factor target → reduced TF activity → impaired extrinsic coagulation → increased minor hemorrhage risk; Grade 2 → hold tisotumab; monitor PT/INR; (4) ALOPECIA: MMAE tubulin class effect; EHS INSIGHT NULL: CAS 2055776-40-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first TF/CD142/coagulation factor III ADC absent; HuMax-TF absent; vcMMAE DAR 4 absent; TF HPV cervical absent; innovaTV 204 ORR 24% absent; innovaTV 301 OS HR 0.70 absent; NIOSH HD Cat 1 absent; 40F MSK New York NY gynecologic oncology pharmacist innovaTV 204/301 cervical cancer 12yr).

Integrating Glyphward into Tisotumab Vedotin AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tisotumab vedotin CAS 2055776-40-8 monitoring data ingestion point — before Cority at Genmab US Plainsboro NJ, before VelocityEHS at Pfizer CentreOne McPherson KS, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; NINETY-FOURTH MECHANISM CLASS — FIRST TISSUE FACTOR (TF; CD142; COAGULATION FACTOR III; F3) ADC EVER FDA APPROVED (BLA 761208 September 20 2021 accelerated; regular June 8 2023; HuMax-TF IgG1 anti-TF antibody; vcMMAE valine-citrulline protease-cleavable linker + MMAE; DAR ~4; TF HPV E6/E7 cervical cancer overexpression ~90%; innovaTV 204 ORR 24.0% DOR 8.3 months; innovaTV 301 OS HR 0.70 11.5 vs 9.5 months; Genmab/Pfizer) [5 pts]; Genmab Plainsboro NJ + Pfizer CentreOne McPherson KS + MSK New York NY [3 pts]; TF coagulation factor ADC target absent; vcMMAE linker-payload absent; innovaTV absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tisotumab_vedotin(cas: str, reading_ugm3: float) -> dict:
    """Scan tisotumab vedotin with ninety-fourth-class first-tf-cd142-adc context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "ninety_fourth_class_first_tissue_factor_tf_cd142_coagulation_factor_iii_adc_humax_tf_igg1_vcmmae_dar_4_tf_hpv_e6_e7_cervical_overexpression_90pct_innovatv_204_orr_24pct_dor_8_3mo_innovatv_301_os_hr_0_70_genmab_pfizer_bla_761208"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, ninety_fourth_class,
    #                    first_tf_cd142_adc, vcmmae_dar4,
    #                    tf_hpv_cervical, innovatv_204_orr_24pct

if __name__ == "__main__":
    r = asyncio.run(scan_tisotumab_vedotin("2055776-40-8", 0.00049))
    print(r)
    # {'hd_category': 1, 'ninety_fourth_class': True,
    #  'first_tf_cd142_adc': True, 'vcmmae_dar4': True,
    #  'tf_hpv_cervical': True, 'innovatv_204_orr_24pct': True}